The suite addresses long-standing bottlenecks in drug development, where fragmented systems and manual, spreadsheet-heavy processes often hinder data integrity. By applying a science-first foundation to query management and safety review, CluePoints aims to transition teams from reactive manual checks to a continuous, decision-driven model. According to Chief Strategy Officer Richard Young, the primary objective is to empower experts to focus on critical data issues rather than managing disconnected review cycles.

Intelligent Query Detection allows study teams to execute user-defined scenarios without waiting for vendor-led software updates, while the Medical & Safety Review module unifies data from disparate sources into a single, patient-centric workflow. Additionally, the Intelligent Medical Coding feature utilizes deep learning to suggest MedDRA and WHODrug codes with up to 99% accuracy. These systems are designed to integrate directly into existing study governance, with the unnamed pharmaceutical partner confirmed to join CluePoints at the SCDM 2026 conference in Raleigh to showcase the platform's impact on production environments.